.Price to Earnings (P/E) since 2012
Difficulty: Beginner
Calculation
AbbVie Inc., P/E, long-term trends, calculation
| P/E | = | Share price1, 2, 3 | ÷ | Earnings per share1 (EPS) | EPS1 | = | Net earnings1 (in millions) |
÷ | No. shares of common stock outstanding2 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2013 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2014 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2015 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2016 | = | ÷ | = | ÷ | ||||||
| Dec 31, 2017 | = | ÷ | = | ÷ |
1 USD $
2 Data adjusted for splits and stock dividends.
3 Close price on the filing date of AbbVie Inc.'s Annual Report.
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Competitors
AbbVie Inc., P/E, long-term trends, comparison to competitors
| AbbVie Inc. | Abbott Laboratories | Allergan PLC | Amgen Inc. | Biogen Inc. | Bristol-Myers Squibb Co. | Celgene Corp. | Eli Lilly & Co. | Gilead Sciences Inc. | Johnson & Johnson | Merck & Co. Inc. | Pfizer Inc. | Regeneron Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dec 31, 2012 | |||||||||||||
| Dec 31, 2013 | |||||||||||||
| Dec 31, 2014 | |||||||||||||
| Dec 31, 2015 | |||||||||||||
| Dec 31, 2016 | |||||||||||||
| Dec 31, 2017 |
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Pharmaceuticals & Biotechnology Sector
AbbVie Inc., P/E, long-term trends, comparison to Pharmaceuticals & Biotechnology sector
| AbbVie Inc. | Pharmaceuticals & Biotechnology | |
|---|---|---|
| Dec 31, 2012 | ||
| Dec 31, 2013 | ||
| Dec 31, 2014 | ||
| Dec 31, 2015 | ||
| Dec 31, 2016 | ||
| Dec 31, 2017 |
Source: Based on data from AbbVie Inc. Annual Reports
Comparison to Health Care Industry
AbbVie Inc., P/E, long-term trends, comparison to Health Care industry
| AbbVie Inc. | Health Care | |
|---|---|---|
| Dec 31, 2012 | ||
| Dec 31, 2013 | ||
| Dec 31, 2014 | ||
| Dec 31, 2015 | ||
| Dec 31, 2016 | ||
| Dec 31, 2017 |
Source: Based on data from AbbVie Inc. Annual Reports
